Literature DB >> 21519949

Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Ferdinando Squitieri1, Vittorio Maglione, Sara Orobello, Francesco Fornai.   

Abstract

Huntington's Disease (HD) is caused by trinucleotide CAG repeat expansion >36 in huntingtin (htt), a protein with several documented functions. The elongated polyglutamine (polyQ) stretch in the N-terminal region of htt leads to dysfunctional and degenerative events in neurons and peripheral tissues. In this study, by extending the analysis to several caspase activities (i.e. caspase 2, 3, 6, 8 and 9), we describe genotype- and time- dependent caspase activity abnormalities, decreased cell viability and a large set of alterations in mitochondria morphology, in cultured blood cells from HD patients. Patients homozygous for CAG repeat mutations and heterozygous with high size mutations causing juvenile onset (JHD) presented significantly increased caspase 2, 3, 6, 8 and 9 activities, decreased cell viability and pronounced morphological abnormalities, compared with cells carrying low mutation size and controls. After cyanide treatment, all caspases increased their activities in homozygous and highly expanded heterozygous cells, caspase 8 and 9 increased also in those cells carrying low-size mutations, remarking their key role as 'caspase initiators' in HD. The remarkable ageing-dependent abnormalities in peripheral cells carrying particularly toxic mutations (i.e. homozygotes' and JHD's blood cells) points out the potential dependence of clinical HD development and progression on either mutated htt dosage or missing wild type htt. Peripheral tissues (i.e. blood cells) may theoretically represent an important tool for studying HD mechanisms and searching for new biomarkers, according to the patients' genotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519949     DOI: 10.1007/s00702-011-0646-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

1.  Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation.

Authors:  Vittorio Maglione; Milena Cannella; Roberto Gradini; Giuliana Cislaghi; Ferdinando Squitieri
Journal:  Mech Ageing Dev       Date:  2005-11-10       Impact factor: 5.432

Review 2.  Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.

Authors:  M Borrell-Pagès; D Zala; S Humbert; F Saudou
Journal:  Cell Mol Life Sci       Date:  2006-11       Impact factor: 9.261

3.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization.

Authors:  A Sawa; G W Wiegand; J Cooper; R L Margolis; A H Sharp; J F Lawler; J T Greenamyre; S H Snyder; C A Ross
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

4.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Authors:  V O Ona; M Li; J P Vonsattel; L J Andrews; S Q Khan; W M Chung; A S Frey; A S Menon; X J Li; P E Stieg; J Yuan; J B Penney; A B Young; J H Cha; R M Friedlander
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

6.  Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

Authors:  Cheryl L Wellington; Lisa M Ellerby; Claire-Anne Gutekunst; Danny Rogers; Simon Warby; Rona K Graham; Odell Loubser; Jeremy van Raamsdonk; Roshni Singaraja; Yu-Zhou Yang; Juliette Gafni; Dale Bredesen; Steven M Hersch; Blair R Leavitt; Sophie Roy; Donald W Nicholson; Michael R Hayden
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Abnormal morphology of peripheral cell tissues from patients with Huntington disease.

Authors:  Ferdinando Squitieri; Alessandra Falleni; Milena Cannella; Sara Orobello; Federica Fulceri; Paola Lenzi; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2009-10-16       Impact factor: 3.575

8.  Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.

Authors:  Thomas Toneff; Liane Mende-Mueller; Ying Wu; Shin-Rong Hwang; Richard Bundey; Leslie M Thompson; Marie-Francoise Chesselet; Vivian Hook
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  Impaired PGC-1alpha function in muscle in Huntington's disease.

Authors:  Rajnish K Chaturvedi; Peter Adhihetty; Shubha Shukla; Thomas Hennessy; Noel Calingasan; Lichuan Yang; Anatoly Starkov; Mahmoud Kiaei; Milena Cannella; Jenny Sassone; Andrea Ciammola; Fernando Squitieri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2009-05-21       Impact factor: 6.150

View more
  11 in total

1.  Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington's disease.

Authors:  Laura Ciarlo; Valeria Manganelli; Paola Matarrese; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Matteo Marconi; Maria Grasso; Roberta Misasi; Maurizio Sorice; Walter Malorni
Journal:  J Lipid Res       Date:  2012-07-06       Impact factor: 5.922

Review 2.  Stem cell therapy for neurological disorders: A focus on aging.

Authors:  Hung Nguyen; Sydney Zarriello; Alexandreya Coats; Cannon Nelson; Chase Kingsbury; Anna Gorsky; Mira Rajani; Elliot G Neal; Cesar V Borlongan
Journal:  Neurobiol Dis       Date:  2018-09-13       Impact factor: 5.996

3.  Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.

Authors:  Mahru C An; Ningzhe Zhang; Gary Scott; Daniel Montoro; Tobias Wittkop; Sean Mooney; Simon Melov; Lisa M Ellerby
Journal:  Cell Stem Cell       Date:  2012-06-28       Impact factor: 24.633

Review 4.  Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease.

Authors:  Maria I Avrutsky; Carol M Troy
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.988

Review 5.  An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity.

Authors:  G Cisbani; F Cicchetti
Journal:  Cell Death Dis       Date:  2012-08-30       Impact factor: 8.469

Review 6.  Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells.

Authors:  Kalina Wiatr; Wojciech J Szlachcic; Marta Trzeciak; Marek Figlerowicz; Maciej Figiel
Journal:  Mol Neurobiol       Date:  2017-05-11       Impact factor: 5.590

Review 7.  The Role of Caspase-2 in Regulating Cell Fate.

Authors:  Vasanthy Vigneswara; Zubair Ahmed
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

8.  Mitochondrial Respiratory Function in Peripheral Blood Cells from Huntington's Disease Patients.

Authors:  Johannes K Ehinger; Saori Morota; Magnus J Hansson; Gesine Paul; Eskil Elmér
Journal:  Mov Disord Clin Pract       Date:  2016-02-11

9.  Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Authors:  Albino Carrizzo; Alba Di Pardo; Vittorio Maglione; Antonio Damato; Enrico Amico; Luigi Formisano; Carmine Vecchione; Ferdinando Squitieri
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

Review 10.  Mitochondrial lipids in neurodegeneration.

Authors:  Andreas Aufschnaiter; Verena Kohler; Jutta Diessl; Carlotta Peselj; Didac Carmona-Gutierrez; Walter Keller; Sabrina Büttner
Journal:  Cell Tissue Res       Date:  2016-07-23       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.